Clinical Trial Update: LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing afatinib to methotrexate in recurrent/metastatic head and neck squamous cell carcinoma after platinum therapy has completed, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2026-01-12